Filter Results:
(1,323)
Show Results For
- All HBS Web
(1,323)
- People (2)
- News (347)
- Research (760)
- Events (2)
- Multimedia (5)
- Faculty Publications (389)
Show Results For
- All HBS Web
(1,323)
- People (2)
- News (347)
- Research (760)
- Events (2)
- Multimedia (5)
- Faculty Publications (389)
- March 1999
- Case
Merck & Co., Inc.: Corporate Strategy, Organization and Culture (A)
By: Michael Beer and Perry Fagan
In the early 1990s, Merck faced a series of challenges because of significant changes in its competitive and regulatory environment (e.g., growth in power of pharmaceutical buyers like managed care organizations led to price pressures and President Clinton's review of... View Details
Keywords: Organizational Change and Adaptation; Business or Company Management; Organizational Culture; Problems and Challenges; Management Practices and Processes; Competitive Strategy; Management Teams; Health Care and Treatment; Governing Rules, Regulations, and Reforms; Situation or Environment; Alignment; Pharmaceutical Industry; United States
Beer, Michael, and Perry Fagan. "Merck & Co., Inc.: Corporate Strategy, Organization and Culture (A)." Harvard Business School Case 499-054, March 1999.
- 2021
- Working Paper
Status and Mortality: Is There a Whitehall Effect in the United States?
By: Tom Nicholas
Do white collar workers with lower social status in the occupational hierarchy die younger? The influential Whitehall studies of British civil servants identified a strong inverse relationship between employment rank and mortality, but we do not know if this effect... View Details
Nicholas, Tom. "Status and Mortality: Is There a Whitehall Effect in the United States?" Harvard Business School Working Paper, No. 21-080, January 2021.
- November 2013
- Case
GlaxoSmithKline in China (A)
By: John A. Quelch and Margaret L. Rodriguez
Four GlaxoSmithKline employees were accused of bribing Chinese health care workers to prescribe the company's drugs. The accusations brought to light the questionable incentive structures of the Chinese health care system and the pressure on companies to adhere to... View Details
Keywords: Public Health; Pharmaceuticals; China; Bribery; CSR; Hong Bao; Health Care; Drug; GlaxoSmithKline; GSK; Witty; Government; Marketing; Health; Health Care and Treatment; Corporate Social Responsibility and Impact; Corporate Strategy; Corporate Governance; Business and Government Relations; Ethics; Pharmaceutical Industry; China; United Kingdom; United States
Quelch, John A., and Margaret L. Rodriguez. "GlaxoSmithKline in China (A)." Harvard Business School Case 514-049, November 2013.
- December 2020 (Revised June 2021)
- Case
France Télécom (A): A Challenging Restructuring
These cases explore the impacts of industry shocks, resulting corporate actions that had a devastating impact on employees, and the legal conviction of corporate leaders for “institutional harassment."
This case series follows the evolution of France... View Details
This case series follows the evolution of France... View Details
Keywords: Health & Wellness; Human Resource Management; Strategic Change; Leadership & Corporate Accountability; Leadership And Change Management; Leadership And Managing People; Change; Restructuring; Crime and Corruption; Ethics; Health; Human Capital; Human Resources; Labor; Labor and Management Relations; Labor Unions; Law; Social Psychology; Strategy; Leadership; Leadership Style; Organizations; Problems and Challenges; Relationships; Crisis Management; Organizational Culture; Employees; Well-being; Telecommunications Industry; Europe; European Union
Montgomery, Cynthia A., and Ashley V. Whillans. "France Télécom (A): A Challenging Restructuring." Harvard Business School Case 721-420, December 2020. (Revised June 2021.)
- November 2013 (Revised September 2015)
- Supplement
GlaxoSmithKline in China (B)
By: John A. Quelch and Margaret L. Rodriguez
In 2013, Chinese investigators detained four GSK employees for allegedly bribing health care staff to sell GSK pharmaceuticals. A month later, GSK's Asia Pacific regional president, Abbas Hussain, said the company would help identify corrupt practices. Two days later,... View Details
Keywords: Public Health; Pharmaceuticals; China; Bribery; CSR; Hong Bao; Health Care; Drug; GlaxoSmithKline; GSK; Witty; Government; Marketing; Health; Health Care and Treatment; Corporate Social Responsibility and Impact; Corporate Strategy; Corporate Governance; Business and Government Relations; Ethics; Pharmaceutical Industry; China; United Kingdom; United States
Quelch, John A., and Margaret L. Rodriguez. "GlaxoSmithKline in China (B)." Harvard Business School Supplement 514-050, November 2013. (Revised September 2015.)
- Teaching
Overview
By: Susanna Gallani
At HBS, Professor Gallani teaches in the Executive Education Program for Leadership Development and in focused Executive Education programs, including Managing Health Care Delivery, Driving Corporate Performance, and several programs focused on the implementation of... View Details
- April 2022
- Teaching Note
CVS Health: Prescription for Transformation
By: Rosabeth Moss Kanter and Catarina Martinez
In 2021, new CEO Karen Lynch (named the most powerful woman in business) considered the next transformation phase for CVS Health (a Fortune 5 corporate giant). The 2018 acquisition of Aetna insurance brought her to the company as part of its long evolution from a... View Details
- Article
Achieving Value in Highly Complex Acute Care: Lessons from the Delivery of Extra Corporeal Life Support
By: Michael Nurok, Jonathan Warsh, Erik Dong, Jeffrey Lopez, Mayumi Kharabi and Robert S. Kaplan
We applied a value (outcomes and cost) analysis to extracorporeal life support (ECLS), a relatively rare but very expensive ICU therapy with highly variable outcomes. To address the outcome component of the value approach, we created guidelines for ECLS delivery; to... View Details
Nurok, Michael, Jonathan Warsh, Erik Dong, Jeffrey Lopez, Mayumi Kharabi, and Robert S. Kaplan. "Achieving Value in Highly Complex Acute Care: Lessons from the Delivery of Extra Corporeal Life Support." NEJM Catalyst (October 31, 2019).
- January 2018 (Revised March 2018)
- Case
Wenzhou Kangning Hospital: Changing Mental Healthcare in China
By: William C. Kirby, Wei Zhang, Yuanzhuo Wang and Nancy Hua Dai
The city of Wenzhou in the Province of Zhejiang, long known in China for entrepreneurship, now hosts the country’s largest privately owned mental health hospital group. This case traces the development of Wenzhou Kangning Hospital Co, Ltd. from founding to just before... View Details
Keywords: Mental Health; Hospital; IPO; China; Zhejiang; Wenzhou; Private Healthcare; Private Hospital; Health Care and Treatment; Private Ownership; Corporate Governance; Growth and Development; Entrepreneurship; Health Industry; China
Kirby, William C., Wei Zhang, Yuanzhuo Wang, and Nancy Hua Dai. "Wenzhou Kangning Hospital: Changing Mental Healthcare in China." Harvard Business School Case 318-054, January 2018. (Revised March 2018.)
- January 2014 (Revised January 2014)
- Case
Henry Schein: Doing Well by Doing Good?
By: Rebecca Henderson, Raffaella Sadun, Aldo Sesia and Russell Eisenstat
Henry Schein Inc., a distributor of supplies to dentist, physician, and veterinary practices, had sales approaching $9 billion and employed nearly 16,000 people. The company had experienced impressive growth under the leadership of Stanley Bergman and his executive... View Details
Keywords: Leadership Development; Strategy Execution; Performance Management; Corporate Culture; Social Responsibility; Mergers & Acquisitions; Joint Ventures; Partnerships; Health Care Industry; Healthcare Logistics Industry; Competitive Advantage; Strategy; Leadership; Global Strategy; Selection and Staffing; Management Style; Organizational Culture; Corporate Social Responsibility and Impact; Health Industry; Health Industry; China; Europe; United States
Henderson, Rebecca, Raffaella Sadun, Aldo Sesia, and Russell Eisenstat. "Henry Schein: Doing Well by Doing Good?" Harvard Business School Case 714-450, January 2014. (Revised January 2014.)
- August 2013 (Revised October 2013)
- Case
MedImmune Ventures
By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details
Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London
Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)
- May 2015 (Revised May 2017)
- Case
Colgate-Palmolive Company: Marketing Anti-Cavity Toothpaste
By: John A. Quelch and Margaret L. Rodriguez
In October 2013, Colgate-Palmolive Company, the world's leading oral care company, was about to launch its new Colgate® Maximum Cavity Protection™ plus Sugar Acid Neutralizer™ toothpaste in Brazil. Oral care category accounted for 46 percent of Colgate's $17.4 billion... View Details
Keywords: New Product Management; Consumer Segmentation; Global Marketing; Corporate Social Responsibility; Healthcare; Sustainability; Health Care and Treatment; Environmental Sustainability; Marketing; Segmentation; Product Development; Product Launch; Corporate Social Responsibility and Impact; Product Positioning; Consumer Products Industry; Brazil; United States
Quelch, John A., and Margaret L. Rodriguez. "Colgate-Palmolive Company: Marketing Anti-Cavity Toothpaste." Harvard Business School Case 515-050, May 2015. (Revised May 2017.)
- April 2016 (Revised July 2019)
- Case
"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A)
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
Keywords: Health Care; Mergers & Acquisitions; Governance; Buyout; Private Equity; Finance; Mergers and Acquisitions; Corporate Governance; Health Care and Treatment; Reports; Business Model; Health Industry; Health Industry; Health Industry; United States
Lietz, Nori Gerardo. "Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A). Harvard Business School Case 216-021, April 2016. (Revised July 2019.)
- September 2014 (Revised February 2015)
- Case
Pfizer and AstraZeneca: Marketing an Acquisition (A)
By: John A. Quelch and James Weber
In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details
Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States
Quelch, John A., and James Weber. "Pfizer and AstraZeneca: Marketing an Acquisition (A)." Harvard Business School Case 515-007, September 2014. (Revised February 2015.)
- January–February 2015
- Article
Heroic Villains: Are Foreign Investors Problems or Solutions in the Ebola Crisis?
By: Debora L. Spar
For months, the news out of West Africa has been unrelentingly grim. As of early December, the devastating Ebola epidemic had infected a reported 17,942 people and killed 6,388, according to the World Health Organization (WHO); the actual toll, which would also account... View Details
Keywords: Ebola; Multinational Corporation; Epidemics; Foreign Investment; Extractive Industries; Multinational Firms and Management; Health Pandemics; Developing Countries and Economies; Government and Politics; Africa
Spar, Debora L. "Heroic Villains: Are Foreign Investors Problems or Solutions in the Ebola Crisis?" Foreign Policy 210 (January–February 2015).
- May 2014 (Revised March 2017)
- Case
Unilever's Lifebuoy in India: Implementing the Sustainability Plan
Unilever's new Global Brand VP must not only revitalize Lifebuoy soap's sagging market performance, but simultaneously impact the health of one billion people worldwide. The latter challenge comes from Unilever's new CEO who has introduced the Unilever Sustainable... View Details
Keywords: Multinational Management; Corporate Social Responsibility; Strategy Implementation; Marketing Strategy; Mission And Purpose; Change Management; International Business; Global; Fast-moving Consumer Goods; Soap; Corporate Social Responsibility and Impact; Health Care and Treatment; Environmental Sustainability; Global Strategy; Developing Countries and Economies; Beauty and Cosmetics Industry; Health Industry; India
Bartlett, Christopher A. "Unilever's Lifebuoy in India: Implementing the Sustainability Plan." Harvard Business School Case 914-417, May 2014. (Revised March 2017.)
- 01 Mar 2023
- News
Turning Point: In Good Company
Aparna Piramal Raje (MBA 2002) (Illustration by Gisela Goppel) Aparna Piramal Raje (MBA 2002) (Illustration by Gisela Goppel) There have been many turning points in my journey of living with bipolar disorder over the last 20 years. HBS has been an integral part of the... View Details